Abstract Tumor nectosis factor (TNF) receptors are key players in inflammation and immune regulation. A new member of this family, termed death receptor-6 (DR6), has been identified. Like other death receptors, DR6 is a type I transmembrane receptor, possesses four extracellular cysteinerich motifs and a cytoplasmic death domain. DR6 is expressed in most human tissues and abundant transcript was detected in heart, brain, placenta, pancreas, thymus, lymph node and several non-lymphoid cancer cell lines. DR6 interacts with TRADD, which has previously been shown to associate with TNFR1. Furthermore, ectopic expression of DR6 in mammalian cells induces apoptosis and activation of both NF-U UB and JNK.
Introduction
Members of the tumor necrosis factor (TNF) receptor family are crucial modulators of in£ammatory and cellular immune responses and mediate a variety of biological functions ranging from cell proliferation, di¡erentiation and apoptosis to cell survival [1^7] . This family of receptors is characterized by several extracellular, cysteine-rich motifs that compose the ligand binding domain [2, 5] . Upon ligation by their cognate ligands, these receptors engage a number of signal transduction pathways, including apoptosis, activation of NF-UB and JNK pathways that modulate the expression of genes involved in the immune and stress response [5] .
Within the TNF receptor family, six members have emerged as a distinct subgroup termed death receptors; they contain a cytoplasmic death domain and activation of these receptors leads to engagement of components of the cell death pathway [1, 3] . Transmission of the death signal is mediated by a series of homophilic protein-protein interactions involving the death domain and death e¡ector domain that was originally de¢ned as being present in the adaptor molecule FADD/MORT1 and the death protease caspase-8 [8] . For example, when the death receptor CD95/Fas is ligated by cognate ligand or agonist antibody, the adaptor molecule FADD and the death protease caspase-8 are recruited to the signalling complex through interactions involving death and death e¡ector domains, respectively [8^10]. On approximation, caspase-8 undergoes an autoactivation, initiating activation of the downstream caspases, cleavage of death substrates and demise of the cell [11^14] . In contrast to CD-95 that directly engages the FADD-caspase-8 pathway [9, 10, 15, 16] , both TNFR1 and death domain-3 (DR3) utilize a primary adaptor molecule termed TRADD, around which assembles the FADD-caspase-8 pathway, an NF-UB activating pathway involving the death domain-containing Ser/Thr kinase RIP and a JNK activating pathway that is mediated by the adaptor molecule TRAF2 [17^23]. Finally, there exists a subsidiary death pathway involving the death domain-containing adaptor RAIDD that binds to caspase-2 and has been shown to be part of the TNFR1 receptor complex, although the exact physiologic relevance of this redundant pathway remains unclear [24, 25] .
Here, we report the identi¢cation and initial characterization of DR6, a new member of the TNF receptor family possessing a cytoplasmic death domain. DR6 induced apoptosis in mammalian cells and was capable of engaging the NF-UB and JNK pathways.
Materials and methods

Expression constructs
DR6(42^655) and DR6 delta(42^460) were cloned into pCMV1FLAG (IBI-Kodak) as in-frame fusions to a NH P -terminal preprotrypsin leader sequence and FLAG tag encoded by the vector. cDNAs were obtained by polymerase chain reaction using DNA oligo primers for DR6: 5P-GGAAGATCTGCCAGAACAGAAGG-CCTCGAAT-3P and 5P-CCATCTTCCTGACCTGCTGTAGTCTA-GAGCC-3P and for DR6 delta: 5P-GGAAGATCTGCCAGAACA-GAAGGCCTCGAAT-3P and 5P-GCCGACCACGAGCGGGCCTA-GTCTAGAGCC-3P. Constructs encoding DR4, FADD, CD95, DR3, TRADD, ICH1-pro, RAIDD and RIP have been described previously [15,17^19,23,26] .
Apoptosis assay
Cell death assays were performed as described [15, 26] . Both HeLa and MCF7 cells were transfected using the lipofectAMINE procedure (Life Technologies, Inc.) according to the manufacturer's instructions.
Co-immunoprecipitation assay
In vivo interaction assays have been described elsewhere [15, 26] . 293 cells were transfected by means of calcium phosphate precipitation.
NF-UB luciferase assay
NF-UB luciferase assays were done as described [15, 26] . plated in 6-well plates and transfected with DR6-expressing plasmid or vector alone at 60^70% con£uence by the lipofectAMINE method according to the manufacturer's instructions. Forty hours post transfection, cell extracts were prepared in lysis bu¡er containing 20 mM HEPES, pH 7.4, 2 mM EDTA, 250 mM NaCl, 0.1% NP-40, 2 Wg/ml leupeptin, 2 Wg/ml aprotinin, 1 mM PMSF, 0.5 Wg/ml benzamide, 1 mM DTT and 1 mM orthovanadate. The C-jun kinase assay was performed by a modi¢ed method as described [27] . T 293 cells were co-transfected with the indicated constructs (6.4 Wg) together with 2.4 Wg of a JNK-myc expression plasmid. After transfection (approximately 36 h), cell extracts were prepared by lysis in NP40 bu¡er (20 mM Tris-HCl, pH 8.0, 137 mM NaCl, 10% glycerol, 2 mM EDTA, 5 mM Na P VO R , 0.5 mM PMSF and 1% NP40) plus protease inhibitor cocktail (BMB). Immunoprecipitation of JNK-myc was done using monoclonal anti-myc antibody (10 Wg, Babco) and immunocomplexes precipitated with 20 Wl protein G-Sepharose (50% slurry, Sigma). The kinase assay utilized 2 Wg GST-Jun(1^79) as substrate, 50 mM ATP and 5 WCi [Q QP P]ATP in 30 Wl kinase bu¡er (30 mM HEPES, pH 7.4, 7 mM MnCl P , 5 mM MgCl P and 1 mM DTT).
Results and discussion
Identi¢cation and molecular cloning of a new member of
the TNF receptor family To identify additional TNF receptor-related molecules, we searched an expressed sequence tag (EST) database using the protein sequence of the extracellular, cysteine-rich, ligand binding domain of TNFR2 [28, 29] . Several human EST cDNA clones were initially identi¢ed. Analyses of these clones revealed one that contained an open reading frame encoding a protein of 655 amino acids (Fig. 1A) . Database searches, protein sequence alignment, and comparative analyses indicated this molecule to be a novel cell surface receptor related to the TNF receptor family and possessing an intracellular death domain (Fig. 1C) . Thus, this new molecule was named death receptor 6, or DR6 (see below).
DR6 had a putative signal sequence (amino acids 1^41), with the mature form predicted to start at amino acid 42 (Gln) [30] . The extracellular portion (amino acids 67^211) contains four TNFR-like cysteine-rich motifs that are most related to those of osteoprotegerin (OPG) and TNFR2 with 36% and 42% amino acid identities, respectively ( Fig. 1B; data not shown). A transmembrane domain (amino acids 351^370) is followed by a 285 amino acids long cytoplasmic portion of the molecule that contains a death domain related to those of all known death receptors (Fig. 1C) , being most related to the death domain of TNFR1 (27.2%) and least like that of DR5 (19.7%). Curiously, unlike other death receptors that have death domains present in their COOH-terminus, the death domain in DR6 was located adjacent to the transmembrane domain followed by a 150 amino acid tail. Interestingly, following the death domain was a putative leucine zipper sequence overlapping with a proline-rich region, reminiscent of a SH3 domain-binding motif (Fig. 1A) [31] . Their functional relevance remains to be discovered.
3.2. DR6 mRNA expression in human tissues and cancer cell lines A 4 kb DR6 transcript was found in most tissues (Fig. 1D) . The transcript was abundant in heart, brain, placenta, pancreas, lymph node, thymus, and prostate. Lower levels were detected in lung, skeletal muscle, kidney, testis, uterus, small intestine, colon, spleen, bone marrow, and fetal liver. However, adult liver and peripheral blood leukocytes expressed little DR6 mRNA. Additionally, smaller transcripts of 3.1 and 2.4 kb were observed in the testis and fetal liver, respectively.
Among human cancer cell lines, abundant transcript levels were detected in several non-lymphoid tumor cells, including cervical carcinoma HeLa S3, colorectal adenocarcinoma SW480, lung carcinoma A549, and melanoma G361 cells. Signi¢cantly, little or no expression was observed in lines of hematopoietic origin (Fig. 2D ).
DR6 induces apoptosis in mammalian cells
Since ectopic expression of death receptors can induce cell death in a ligand-independent manner [15, 16, 19, 20 ,26], we tested if DR6 could induce apoptosis upon overexpression. When HeLa S3 cervical carcinoma cells were transfected with a DR6-expressing construct, 43% of the transfected cells underwent morphological changes characteristic of apoptosis ( Fig. 2A) . As expected, deletion of the putative death domain (DR6 delta) abolished its killing activity. Signi¢cantly, DR6 was unable to induce cell death in human breast carcinoma MCF7 cells, although they were very sensitive to DR4 killing ( Fig. 2A and not shown) , suggesting that the cell death pathway engaged by DR6 may be distinct from that engaged by other death receptors. Alternatively, the apoptotic activity of DR6 may be modulated by other signaling pathways it activates (see below) or ligand binding may be required to unveil its full killing capacity. Further work will be needed to address this issue. 
Interaction of DR6 with adaptor molecules in vivo
Death receptors utilize the adaptor molecules FADD (for CD95) or both TRADD and FADD (for TNFR1 and DR3) to transmit the death signal [15, 16, 19, 20] . We thus determined if DR6 could bind any of these adaptor molecules in human embryonic kidney 293 cells. DR6 did not interact with FADD, although the association between CD95 and FADD was readily detected under similar conditions (Fig. 2B) . Interestingly, DR6 was found to associate with TRADD, although the interaction was weaker than that between DR3 and TRADD (Fig. 2C ). This observation is consistent with the observation that DR6 has a weaker killing ability. Alternatively, DR6 may use a TRADD-related molecule as an adaptor, or the observed association might be bridged by another adaptor protein. Interaction was not detectable between DR6 and RAIDD or RIP, two other adaptor molecules known to be recruited to the TNFR1 and DR3 signalling complexes (Fig. 2D,E) .
DR6 activates NF-UB
Both TNFR1 and DR3 can engage a signal transduction pathway that leads to the activation of NF-UB [5, 19, 20, 28] . The ability of DR6 to activate NF-UB was tested in a luciferase reporter assay and was found to induce NF-UB activation in a dose-dependent manner (Fig. 3, left) . Presumably overexpressing the receptor allowed it to achieve an active con¢g-uration that was competent to signal the NF-UB system. Interestingly, the cytoplasmic deletion of DR6 that abolished its apoptotic activity similarly abrogated its ability to activate NF-UB (Fig. 3, right) , suggesting that these two signaling pathways may be mediated by a common receptor-proximal adapter molecule.
Ectopic expression of DR6 induces JNK activation
JNK activation is known to be induced by several TNF receptors including TNFR1 and CD40 [5, 21, 22, 28] . We next determined whether overexpression of DR6 could lead to JNK activation using an in vitro kinase assay. DR6 was found to induce JNK activation in a dose-dependent manner (Fig. 4A) . The cytoplasmic truncation that attenuated cell death or NF-UB activation had surprisingly little e¡ect on JNK activation (Fig. 4B ). This would be consistent with the notion that JNK activation is mediated by a cytoplasmic segment di¡erent from that responsible for apoptosis and NF-UB induction. It is noteworthy that two potential TRAF-binding motifs are present adjacent to the transmembrane domain (PRQDP, amino acids 381^385 and PTQNR, amino acids After transfection (at 40 h), cell extracts were prepared and assayed for JNK activity as described in Section 2. B: Cotransfection of 293 cells was performed with the indicated constructs together with JNK-myc-expressing plasmid using the calcium phosphate precipitation method. Thirty-six hours post transfection, cell lysates were prepared and assayed for JNK activity as described in Section 2. JNK-myc was immunoprecipitated with anti-myc and detected by blotting with anti-myc-HRP (BMB, bottom panel). FLAG-tagged CD-40, DR6 and DR6 delta were immunoprecipitated with anti-FLAG M2 a¤nity gel and detected by blotting with anti-FLAG antibody (not shown). Fig. 3 . DR6 mediates NF-UB activation. Cotransfection of 293 cells was performed with the indicated expression constructs and a NF-UB luciferase reporter construct. After transfection (at 36 h), cell extracts were prepared and luciferase activities determined as described [19, 26] . Transfection e¤ciency was monitored by L-galactosidase activity. A portion of the transfected cells was used to monitor expressioin of DR6 or DR6 delta (not shown). 2 Wg of each DNA construct was used for the luciferase assays shown on the left. Fig. 2 . DR6 induces apoptosis in mammalian cells. A: Ectopic expression of DR6 induces apoptosis in HeLa cells, but not in MCF7 cells. HeLa and MCF7 cells were cotransfected with an empty vector, DR6, DR6 delta or DR4 together with a L-galactosidase-expressing reporter construct using a lipofectamine method according to the manufacturer's instructions (BRL). Nineteen hours after transfection, cells were stained with 5-bromo-4-chloro-3-indoxyl-L-D-galactopyranoside (X-Gal) and examined [15] . The data (mean þ S.D.) represent the percentage of round, apoptotic cells as a function of total L-galactosidase-positive cells (n = 4). B: Interaction of DR6 with adapter molecules. 293 cells were cotransfected with the indicated expression constructs using a calcium phosphate precipitation method. After transfection (at 38^40 h), cell lysates were prepared and the FLAG-tagged death receptors immunoprecipitated with FLAG M2 a¤nity gel (IBI-Kodak) and the presence of FADD, myc-tagged TRADD and RIP (myc-TRADD and myc-RIP), or RAIDD detected by immunoblotting with polyclonal antibody to FADD, horseradish peroxidase (HRP)-conjugated antibody to myc (BMB), or polyclonal antibody to RAIDD, respectively. Numbers to the left of the gels indicate molecular sizes in kilodaltons. 6 400^404) [32^34] . Mutational analysis will be required to understand their functional signi¢cance.
In conclusion, we have identi¢ed a novel death domaincontaining TNF receptor designated DR6. DR6 engages a cell death pathway di¡erent from those initiated by the CD95, TNFR1 or TRAIL/Apo2L receptors. In addition, DR6 also activates NF-UB and JNK, two signaling pathways shared by TNFR1. Although its physiological function is unknown, it is probable that, like the other members of the TNF receptor family, DR6 may play a role in in£ammatory responses and immune regulation. Identi¢cation of the ligand and targeted gene disruption will further our understanding of the physiologic role of this new member of the TNF receptor family.
